Like the other cannabinoids, its effects are produced through interaction with the receptors of the endocannabinoid system of the human body. But unlike THC, CBC binds quite badly with the CB1 receptors in the brain, which is where THC exerts its psychoactive effects. In fact, CBC seems to interact on receptors other than the best-known CB1 and CB2 receptors.
Research indicates that CBC binds more effectively with the TRPV1 and the TRPA1 receptors, both linked to the perception of pain and acting as molecular integrators of physical and thermal stimuli.
And when CBC activates these receptors, it leads to the release of higher levels of natural endocannabinoids, such as anandamide, also known as the "bliss molecule". This explains the different way in which CBC acts: while THC and other cannabinoids are directly coupled to their respective receptors (such as CB1 and CB2), CBC indirectly activates these cannabinoid receptors through the production of anandamide, with significant implications for its role in pain relief.
CBC can also play a fundamental role in the "
entourage effect", in which cannabinoids act synergistically to modulate the overall effect of cannabis.
Thus, a study found that when used together, CBC and THC can control inflammation more effectively than when used separately.